SENISCA Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
Seed
- Latest Deal Amount
-
$4.71M
- Investors
-
12
SENISCA General Information
Description
Developer of anti-aging oligonucleotide therapeutics designed to deliver effective pharmaceutical treatments for treating age-related chronic diseases. The company provides a new generation of oligonucleotide-based interventions to turn back the aging clock in old cells and to target the diseases and aesthetic signs of aging by restoring the ability of cells to fine-tune the expression of their genes, enabling people to live healthily for a longer period and rejuvenate aged cells.
Contact Information
Website
www.senisca.comCorporate Office
- RILD Building
- Barrack Road
- Exeter EX2 5DW
- England, United Kingdom
Corporate Office
- RILD Building
- Barrack Road
- Exeter EX2 5DW
- England, United Kingdom
SENISCA Timeline
SENISCA Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Seed Round | 20-Feb-2024 | $4.71M | Completed | Pre-Clinical Trials | ||
| 9. Accelerator/Incubator | 01-Dec-2023 | Completed | Pre-Clinical Trials | |||
| 8. Grant | 20-Apr-2023 | Completed | Pre-Clinical Trials | |||
| 7. Seed Round | 15-Feb-2022 | Completed | Pre-Clinical Trials | |||
| 6. Grant | Completed | Pre-Clinical Trials | ||||
| 5. Grant | 01-Jan-2022 | Completed | Pre-Clinical Trials | |||
| 4. Seed Round | 23-Feb-2021 | Completed | Pre-Clinical Trials | |||
| 3. Accelerator/Incubator | 01-Jan-2020 | Completed | Startup | |||
| 2. Grant | $96.5K | Completed | Startup | |||
| 1. University Spin-Out | 01-Jan-2020 | Completed | Startup |
SENISCA Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 41,181 | $0.001265 | $38.7 | $38.7 | 1x | $38.7 | 18.95% | |
| Ordinary | 1,452 | $0.001265 | $34.83 | $34.83 | 1x | $34.83 | 0.67% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
SENISCA Comparisons
Industry
Financing
Details
SENISCA Competitors (1)
One of SENISCA’s competitors is Alnylam Pharmaceuticals (Royalties and Commercial Milestones for Inclisiran based in United States), a Private Equity-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals (Royalties and Commercial Milestones for Inclisiran based in United States) | Private Equity-Backed | Cambridge, MA |
SENISCA Patents
SENISCA Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202508255-D0 | Combination | Pending | 28-May-2025 | ||
| GB-202508258-D0 | Combination | Pending | 28-May-2025 | ||
| GB-202508259-D0 | Combination | Pending | 28-May-2025 | ||
| GB-202508263-D0 | Combination | Pending | 28-May-2025 | ||
| GB-202508265-D0 | Combination | Pending | 28-May-2025 |
SENISCA Signals
SENISCA Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Exeter Innovation | Accelerator/Incubator | |||
| APEX Ventures | Venture Capital | Minority | ||
| LifeSpan Vision Ventures | Venture Capital | Minority | ||
| QantX | Venture Capital | Minority | ||
| Innovate UK | Government |
SENISCA FAQs
-
When was SENISCA founded?
SENISCA was founded in 2020.
-
Where is SENISCA headquartered?
SENISCA is headquartered in Exeter, United Kingdom.
-
What is the size of SENISCA?
SENISCA has 15 total employees.
-
What industry is SENISCA in?
SENISCA’s primary industry is Drug Discovery.
-
Is SENISCA a private or public company?
SENISCA is a Private company.
-
What is the current valuation of SENISCA?
The current valuation of SENISCA is .
-
What is SENISCA’s current revenue?
The current revenue for SENISCA is .
-
How much funding has SENISCA raised over time?
SENISCA has raised $10.7M.
-
Who are SENISCA’s investors?
Exeter Innovation, APEX Ventures, LifeSpan Vision Ventures, QantX, and Innovate UK are 5 of 12 investors who have invested in SENISCA.
-
Who are SENISCA’s competitors?
Alnylam Pharmaceuticals (Royalties and Commercial Milestones for Inclisiran based in United States) is a competitor of SENISCA.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process